147 related articles for article (PubMed ID: 35347661)
1. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2022 Jun; 39(6):3059-3060. PubMed ID: 35347661
[No Abstract] [Full Text] [Related]
2. Correction to: Patterns of Use and Clinical Outcomes with Long-Acting Somatostatin Analogues for Neuroendocrine Tumors: A Nationwide French Retrospective Cohort Study in the Real-Life Setting.
Harrow B; Fagnani F; Nevoret C; Truong-Thanh XM; de Zélicourt M; de Mestier L
Adv Ther; 2023 Jan; 40(1):387-388. PubMed ID: 36315341
[No Abstract] [Full Text] [Related]
3. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
[TBL] [Abstract][Full Text] [Related]
4. Preparation of Long-Acting Somatostatin and GnRH Analogues and Their Applications in Tumor Therapy.
Yu F; Zhang T; Fu F; Wang A; Liu X
Curr Drug Deliv; 2022; 19(1):5-16. PubMed ID: 34951573
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine gastrointestinal tumors--a condensed overview of diagnosis and treatment.
Oberg K
Ann Oncol; 1999; 10 Suppl 2():S3-8. PubMed ID: 10399026
[TBL] [Abstract][Full Text] [Related]
6. Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.
Arnold R; Simon B; Wied M
Digestion; 2000; 62 Suppl 1():84-91. PubMed ID: 10940693
[TBL] [Abstract][Full Text] [Related]
7. Prescription patterns of long-acting somatostatin analogues.
Machado-Alba JE; Machado-Duque ME
SAGE Open Med; 2017; 5():2050312117694795. PubMed ID: 28540043
[TBL] [Abstract][Full Text] [Related]
8. Long-acting somatostatin analogues in the treatment of unresectable/metastatic neuroendocrine tumors.
Enzler T; Fojo T
Semin Oncol; 2017 Apr; 44(2):141-156. PubMed ID: 28923213
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and somatostatin receptors: from basic concepts to clinical applications.
De Martino MC; Hofland LJ; Lamberts SW
Prog Brain Res; 2010; 182():255-80. PubMed ID: 20541669
[TBL] [Abstract][Full Text] [Related]
10. When and How to Use Somatostatin Analogues.
de Herder WW
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):549-555. PubMed ID: 30098715
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter Experience with Long-Acting Somatostatin Analogues in Patients with Congenital Hyperinsulinism.
van der Steen I; van Albada ME; Mohnike K; Christesen HT; Empting S; Salomon-Estebanez M; Greve Rasmussen A; Verrijn Stuart A; van der Linde AAA; Banerjee I; Boot AM
Horm Res Paediatr; 2018; 89(2):82-89. PubMed ID: 29241206
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
Simonenko VB; Dulin PA; Makanin MA
Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
[TBL] [Abstract][Full Text] [Related]
13. Hypoglycemia induced by long-acting somatostatin analogues in a patient with nonfunctional neuroendocrine tumor.
Unek IT; Celtik A; Yener S; Yavuzsen T; Alacacioglu A; Cokmert S; Oztop I; Demirkan B; Dicle O; Sagol O; Bekis R; Yilmaz U
J BUON; 2009; 14(1):135-8. PubMed ID: 19365885
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors.
Colao A; Faggiano A; Pivonello R
Prog Brain Res; 2010; 182():281-94. PubMed ID: 20541670
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.
Oberg K
Ann Oncol; 2001; 12 Suppl 2():S111-4. PubMed ID: 11762335
[TBL] [Abstract][Full Text] [Related]
16. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
17. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
[TBL] [Abstract][Full Text] [Related]
18. [Biotherapy of neuroendocrine tumors].
Chanson P; Ducreux M
Rev Prat; 2002 Feb; 52(3):280-4. PubMed ID: 11925718
[TBL] [Abstract][Full Text] [Related]
19. Real-world treatment patterns of gastrointestinal neuroendocrine tumors: A claims database analysis.
Benson AB; Broder MS; Cai B; Chang E; Neary MP; Papoyan E
World J Gastroenterol; 2017 Sep; 23(33):6128-6136. PubMed ID: 28970728
[TBL] [Abstract][Full Text] [Related]
20. Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues.
Pusceddu S; Vernieri C; Di Maio M; Marconcini R; Spada F; Massironi S; Ibrahim T; Brizzi MP; Campana D; Faggiano A; Giuffrida D; Rinzivillo M; Cingarlini S; Aroldi F; Antonuzzo L; Berardi R; Catena L; De Divitiis C; Ermacora P; Perfetti V; Fontana A; Razzore P; Carnaghi C; Davì MV; Cauchi C; Duro M; Ricci S; Fazio N; Cavalcoli F; Bongiovanni A; La Salvia A; Brighi N; Colao A; Puliafito I; Panzuto F; Ortolani S; Zaniboni A; Di Costanzo F; Torniai M; Bajetta E; Tafuto S; Garattini SK; Femia D; Prinzi N; Concas L; Lo Russo G; Milione M; Giacomelli L; Buzzoni R; Delle Fave G; Mazzaferro V; de Braud F
Gastroenterology; 2018 Aug; 155(2):479-489.e7. PubMed ID: 29655834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
